Quantification, isolation and structural determination of bradykinin and hydroxyprolyl-bradykinin in tumor ascites - PubMed (original) (raw)
Quantification, isolation and structural determination of bradykinin and hydroxyprolyl-bradykinin in tumor ascites
Y Matsumura et al. Adv Exp Med Biol. 1989.
Abstract
The presence of kinins in ascitic tumor fluids from rodents and human patients was identified and quantified. In bioassay, kinin content was found to be 1 to 40 ng/ml, and by enzyme immunoassay, 0.6 to 2.5 ng/ml. In particular, a high kinin content, 40 ng/ml, was found in the ascites of a gastric cancer patient by bioassay. Purification of this kinin in the ascites from the gastric cancer patient was performed by ethanol precipitation, gel filtration and reversed-phase high-performance liquid chromatography (HPLC). Two peaks (peak A and peak B) showed kinin activity. Peak A did not correspond to either bradykinin or other known kinins, such as lysyl-bradykinin and T-kinin, whereas peak B corresponded to bradykinin. Peak A contained 8 amino acid residues from bradykinin minus one proline plus an additional hydroxyproline. Sequence analysis of peak A showed that the proline at the third amino acid residue of bradykinin was replaced by hydroxyproline. The retention time of peak A on reversed-phase HPLC was exactly the same as that of synthetic hydroxyprolyl3-bradykinin (Hyp3-bradykinin) but was distinguishable from des-Pro3-bradykinin. Thus, these results demonstrate for the first time the presence of Hyp3-bradykinin in mammalian system.
Similar articles
- Degradation pathway of kinins in tumor ascites and inhibition by kininase inhibitors: analysis by HPLC.
Matsumura Y, Maeda H, Kato H. Matsumura Y, et al. Agents Actions. 1990 Mar;29(3-4):172-80. doi: 10.1007/BF01966443. Agents Actions. 1990. PMID: 2160186 - Purification and identification of [hydroxyprolyl3]bradykinin in ascitic fluid from a patient with gastric cancer.
Maeda H, Matsumura Y, Kato H. Maeda H, et al. J Biol Chem. 1988 Nov 5;263(31):16051-4. J Biol Chem. 1988. PMID: 3182782 - Isolation of [hydroxyproline3]Lysyl-bradykinin formed by kallikrein from human plasma protein.
Sasaguri M, Ikeda M, Ideishi M, Arakawa K. Sasaguri M, et al. Adv Exp Med Biol. 1989;247A:539-44. doi: 10.1007/978-1-4615-9543-4_83. Adv Exp Med Biol. 1989. PMID: 2603820 - [A role of kallikrein-kinin system in gut diseases].
Zelawski W, Witalińska-Labuzek J, Stadnicki A. Zelawski W, et al. Wiad Lek. 2005;58(5-6):331-4. Wiad Lek. 2005. PMID: 16238127 Review. Polish. - The purification and structural elucidation of bradykinin--a reminiscence of 1960.
Lewis GP. Lewis GP. Immunopharmacology. 1999 Sep;43(2-3):97-101. doi: 10.1016/s0162-3109(99)00127-7. Immunopharmacology. 1999. PMID: 10596839 Review. No abstract available.
Cited by
- The link between infection and cancer: tumor vasculature, free radicals, and drug delivery to tumors via the EPR effect.
Maeda H. Maeda H. Cancer Sci. 2013 Jul;104(7):779-89. doi: 10.1111/cas.12152. Epub 2013 Apr 22. Cancer Sci. 2013. PMID: 23495730 Free PMC article. Review. - Degradation pathway of kinins in tumor ascites and inhibition by kininase inhibitors: analysis by HPLC.
Matsumura Y, Maeda H, Kato H. Matsumura Y, et al. Agents Actions. 1990 Mar;29(3-4):172-80. doi: 10.1007/BF01966443. Agents Actions. 1990. PMID: 2160186
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical